| Date Filed | Type | Description |
| 06/13/2011 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/06/2011 |
8-K
| Quarterly results |
| 06/02/2011 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 06/01/2011 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 06/01/2011 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 06/01/2011 |
PRN
| Grifols and Talecris Biotherapeutics Announce the FTC Has Accepted the Consent Agreement for Public Comment |
| 05/04/2011 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/02/2011 |
8-K
| Form 8-K - Current report |
| 05/02/2011 |
PRN
| Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement with FTC Staff |
| 04/27/2011 |
8-K
| Form 8-K - Current report |
| 04/27/2011 |
10-Q
| Quarterly Report for the period ended March 31, 2011 |
| 04/07/2011 |
ARS
| Form ARS - Annual Report to Security Holders |
| 03/31/2011 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/04/2011 |
PRN
| Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders |
| 03/04/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 03/04/2011 |
PRN
| Grifols and Talecris Announce the Outside Date of Their Merger Agreement has been Extended to June 30, 2011 |
| 03/03/2011 |
PRN
| Talecris Biotherapeutics Receives EU Orphan Drug Designation for Plasmin (Human) as a Treatment for Acute Peripheral Arterial Occlusion |
| 02/23/2011 |
10-K
| Annual Report for the period ended December 31, 2010 |
| 02/23/2011 |
8-K
| Form 8-K - Current report |
| 02/22/2011 |
SC 13D/A
| Talecris Biotherapeutics Holdings Corp. has filed a Schedule 13D for Talecris Biotherapeutics Holdings Corp. |
| 02/17/2011 |
8-K
| Form 8-K - Current report |
| 02/15/2011 |
SC 13G
| PAULSON & CO INC reports a 8.8% stake in Talecris Biotherapeutics |
| 02/15/2011 |
PRN
| NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition |
| 02/14/2011 |
PRN
| Talecris Shareholders Approve Merger with Grifols During Special Meeting of Shareholders |
| 02/11/2011 |
8-K
| Form 8-K - Current report |
| 02/11/2011 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 02/10/2011 |
SC 13G/A
| Capital Research Global Investors reports a 0% stake in Talecris Biotherapeutics Holdings Corp. |
| 02/08/2011 |
PRN
| Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2010 Financial Results |
| 02/04/2011 |
8-K
| Other Events |
| 02/04/2011 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 01/14/2011 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 12/14/2010 |
8-K
| Form 8-K - Current report |
| 11/05/2010 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 10/28/2010 |
10-Q
| Quarterly Report for the period ended September 30, 2010 |
|